GLRX and cancer: Many types of cancer have been shown to be dependent on redox-regulating mechanisms, such as the glutaredoxin and thioredoxin systems, and are therefore vulnerable to changes and offer a promising anticancer target (Trachootham et al., 2009; Hegedus et al., 2018; Postovit et al., 2018; Mohammadi et al., 2019).